Pirtobrutinib, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN StudyAnthony R. Mato, Wojciech Jurczak, Manish R. Patel et al.|Blood|2021Cited by 15